Monday, 5 October 2026
Unapproved Weight Loss Drug Retatrutide Sparks Demand Despite Risks
IEP Gaps

Unapproved Weight Loss Drug Retatrutide Sparks Demand Despite Risks

Retatrutide, an unapproved weight loss drug, sparks demand despite risks, offering potential for non-responders to GLP-1 medications.

By Sulastri Dolla  •  18/09/2026
Oral weight-loss drugs clash on convenience and side effects
Budget Cuts

Oral weight-loss drugs clash on convenience and side effects

Compare oral weight-loss drugs like Wegovy and Foundayo for convenience, side effects, and real-world effectiveness in 2024’s evolving market.

By Khairunisa Pauzi  •  14/09/2026